This is not the most recent version of the article. View current version (21 OCT 2013)

Intervention Protocol

You have free access to this content

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

  1. Theresa A Lawrie1,*,
  2. Roy Rabbie2,
  3. Clemens Thoma3,
  4. Jo Morrison4

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010482


How to Cite

Lawrie TA, Rabbie R, Thoma C, Morrison J. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010482. DOI: 10.1002/14651858.CD010482.

Author Information

  1. 1

    Royal United Hospital, The Cochrane Gynaecological Cancer Group, Bath, UK

  2. 2

    Epsom and St Helier University Hospitals NHS Trust, Department of Respiratory Medicine, London, UK

  3. 3

    University of Oxford, Nuffield Department of Obstetrics & Gynaecology, Oxford, UK

  4. 4

    Musgrove Park Hospital, Department of Obstetrics and Gynaecology, Taunton, Somerset, UK

*Theresa A Lawrie, The Cochrane Gynaecological Cancer Group, Royal United Hospital, Education Centre, Bath, BA13NG, UK. tess@lawrie.com.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (21 OCT 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Our aim is to conduct a comprehensive systematic review of the literature to clarify the role of pegylated liposomal doxorubicin, either alone or in combination, in the first-line treatment of epithelial ovarian cancer.